Everest is a Finalist for the Fierce Outsourcing Awards
April 13, 2026

Everest Clinical Research Named Finalist of Fierce Outsourcing Awards for Excellence in Client Partnership

Everest Clinical Research is pleased to announce it has been named a finalist in the Excellence in Client Partnership category for the Fierce Outsourcing Awards. The awards recognize organizations that demonstrate outstanding collaboration, responsiveness, and commitment to client success across the life sciences industry.

As part of its submission, Everest highlighted two case studies involving highly complex clinical trials that required meticulous operational execution and close coordination across stakeholders. These examples demonstrated Everest’s ability to navigate novel scenarios, apply deep experience and critical-thinking to problem-solving, and deliver reliable outcomes while maintaining high standards of quality and compliance.

“We are honored to be named a finalist for Excellence in Client Partnership,” said Jin Dai, CEO of Everest Clinical Research. “Everest’s culture is built on high‑touch customer service and operating as a true extension of our clients’ teams. We bring a can‑do mindset and deep experience to every study, working side by side with our partners to navigate complexity and drive successful clinical outcomes. Being recognized in this category reflects who we are as an organization and how we approach every client relationship.”

Recent Posts

Best CRO
Everest Clinical Research Named Finalist for Best Full-Service CRO Award
Everest Clinical Research acquires Firma Data Services
Everest Clinical Research Expands Global Biometrics Capabilities with Acquisition of Firma Clinical Research’s Data Services Business Unit
Planning for an ISS and ISE
The Top ISS and ISE Mistakes That Delay Regulatory Submissions
European Clinical Trial Strategy
Building a Smarter European Country Strategy for Your Next Oncology Study: Four Strategic Considerations
Outside of FDA Offices
One Pivotal Trial as the “New Default” for FDA Approval: Is FDA Really Changing Course?

Share This Post